| Literature DB >> 32595812 |
Raymundo Vera-Pineda1, Edgar Francisco Carrizales-Sepulveda1, Adrian Camacho-Ortiz2, Laura Nuzzolo-Shihadeh2, Francisco Cruz-Ramos3, Alejandro Ordaz-Farias3, Mario Alberto Benavides-Gonzalez1, Gabriel Carranza-Villegas1.
Abstract
Although coronavirus disease 2019 (COVID-19) manifests in most cases with respiratory symptoms, other presentations can occur. Direct damage to the cardiovascular system has been reported and recently, acute myocardial injury has been identified as a risk factor for mortality. Transthoracic echocardiography is a non-invasive tool that allows the detection of myocardial damage with validated markers (left ventricular ejection fraction and global longitudinal strain). Herein, we present the echocardiographic findings in four patients with COVID-19. All cases had acute respiratory distress syndrome (100%). Three out of four had elevated levels of creatine kinase and creatine kinase myocardial band. One case had ventricular concentric remodeling (25%). All cases (100%) had altered ventricular function: two had a reduced ejection fraction (50%) and, of those available for global longitudinal strain analysis, all had abnormal global longitudinal strain (100%). One case was found to have a tricuspid vegetation of 12 × 10 mm with no other manifestation of endocarditis. All of our cases had left ventricular dysfunction as assessed by echocardiography. One of our patients had a vegetation in the tricuspid valve. Two of our cases had a reduced ejection fraction. The importance of acute cardiac injury in COVID-19 has recently been established. A recent study found it to be an independent risk factor for mortality in patients with this disease. Information regarding echocardiographic characteristics of this population is scarce. Further research to elucidate the impact of these characteristics on morbidity and mortality is urgently needed. Copyright 2020, Vera-Pineda et al.Entities:
Keywords: COVID-19; Heart failure; Transthoracic echocardiography
Year: 2020 PMID: 32595812 PMCID: PMC7295558 DOI: 10.14740/cr1084
Source DB: PubMed Journal: Cardiol Res ISSN: 1923-2829
Baseline Clinical and Laboratory Characteristics
| Variable | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| Gender | Male | Male | Male | Male |
| Age (years) | 76 | 64 | 66 | 26 |
| Comorbidities | Prostate cancer | HIV | None | None |
| White blood cell count, /µL | 11.2 | 8.6 | 14.3 | 8.1 |
| Lymphocytes, /µL | 0.306 | 0.483 | 0.563 | 1.4 |
| Serum creatinine, mg/dL | 0.9 | 0.9 | 5.3 | 0.8 |
| Aminotransferase | ||||
| Aspartate, U/L | 44 | 96 | 99 | 68 |
| Alanine, U/L | 40 | 108 | 43 | 85 |
| Albumin, g/dL | 2.1 | 2 | 2.7 | 3.4 |
| hs-CRP, mg/dL | 27 | 20.6 | 23.1 | 11.3 |
| ARDS | Yes | Yes | Yes | Yes |
| PaO2/FiO2 ratio | 59 | 66 | 180 | 258 |
| Cardiac injury markers | ||||
| hs-TpnI, ng/L | 2.8 | 5.4 | 5.6 | 1.4 |
| CK, U/L | 721 | 868 | 517 | 50 |
| CK-MB, U/L | 29 | 35.3 | 26.5 | n/a |
| LDH, U/L | 312 | 259 | 424 | 317 |
hs-CRP: high-sensitivity C-reactive protein; ARDS: acute respiratory distress syndrome; hs-TpnI: high-sensitivity troponin I; CK: creatine kinase; CK-MB: creatine kinase myocardial band; LDH: lactate dehydrogenase.
Echocardiographic characteristics and Recommended Reference Values
| Variable | Case 1 | Case 2 | Case 3 | Case 4 | Reference value |
|---|---|---|---|---|---|
| LV septal thickness, cm | 0.8 | 1.2 | 1.1 | 0.7 | 0.6 - 1 |
| Posterior wall thickness, cm | 0.8 | 1.1 | 0.8 | 0.9 | 0.6 - 1 |
| LV indexed mass, g/m2 | 80.7 | 56.5 | 81.4 | 73.6 | 49 - 115 |
| Relative wall thickness | 0.31 | 0.47 | 0.32 | 0.37 | 0.24 - 0.42 |
| VfdVI MOD BP | 38 | 76 | n/a | 83 | 62 - 150 |
| VfsVI MOD BP | 25 | 26 | n/a | 56 | 21 - 61 |
| LVEF, % | 35 | 66 | 65 | 33 | 52 - 72 |
| Left atrial indexed volume, mL/m2 | 21.8 | 15.4 | 11.1 | < 34 | |
| Average GLS, % | -14 | -18 | n/a | -14 | < -18.5% |
| Aplax GLS, % | -12 | -18 | n/a | -14 | < -18.5% |
| a4C GLS, % | -13 | -18 | n/a | -13 | < -18.5% |
| a2C GLS, % | -15 | -19 | n/a | -14 | < -18.5% |
| TAPSE, mm | 25 | 26 | 20 | 20 | > 18 |
| S wave, cm/s | 0.18 | 0.7 | 0.18 | 0.12 | > 0.095 |
| RV basal diameter, mm | 33 | 34 | 47 | 39 | 25 - 41 |
| RV mid-cavity diameter, mm | 29 | 22 | 45 | 34 | 19 - 35 |
| MV E wave velocity, m/s | 0.5 | 0.83 | 0.54 | 0.38 | > 50 |
| MV deceleration time, ms | 210 | 218 | 185 | 147 | > 200 |
| E/A ratio | 0.63 | 1.03 | 0.69 | 0.44 | ≥ 0.8 |
| Septal e′ velocity, m/s | 0.05 | 0.08 | 0.07 | 0.1 | > 7 |
| Lateral e′ velocity, m/s | 0.1 | 0.09 | 0.1 | 0.1 | > 10 |
| E/e′ ratio | 6.6 | 9.66 | 6.27 | 3.78 | < 10 |
Data are shown as frequencies (%) and median (min. - max.) or mean ± SD. LV: left ventricular; LVEF: LV ejection fraction; GLS: global longitudinal strain; a4C: apical four-chamber view; APLAX: apical long axis view; a2C: apical two-chamber view; TAPSE: tricuspid annulus plane systolic excursion; RV: right ventricular; MV: mitral valve; n/a: not available.
Figure 1(a) Modified a4c view showing the tricuspid vegetation of case 3. (b) Peak GLS showing decreased values in the inferolateral and inferoseptal territories of case 4. a4C: apical four-chamber view; GLS: global longitudinal strain.